BFM 89.9
The Business Station
Recommended
26 mins
23 mins
26 mins
Merck & Co’s oral antiviral for COVID-19 is being called a “game-changer”, as it would be the first pill available to treat early infection. In another first, the company has agreed to a licensing deal that will allow the drug to be made and sold cheaply in 105 low-income countries. We ask Sangeeta Shashikant, Programme Director on Development & Intellectual Property, Third World Network, whether this move will be enough to make the drug accessible, especially when rich countries look set to hoard supplies amid already existing vaccine inequity.
Listen to Part 1 here, where we explore how molnupiravir works and how it could change the way COVID-19 is managed.
Image credit: The Intercept
Producer: Lim Sue Ann and Tee Shiao Eek
The Bigger PictureHealth & LivingCOVID-19Merckmolnupiravirantiviralremdesivirequitygenericintellectual propertymedicines patent poolIP waiver
Share:
Recommended
May 10
·
23 minsWhat It Takes To Get Your Bread Right
May 9
·
26 minsConfronting Bullying In The Workplace
Recent episodes
0
Latest stories
Podcasts · May 9 · 7:00AM
The Nutcracker
20 mins
Podcasts · May 9 · 20 mins
The Nutcracker
Videos · May 9 · 7:00AM
Anak Tertinggal Dalam Kereta
2 mins
Podcasts · May 9 · 4:00AM
Mall-aysia: Why Are We Still Building Malls?
16 mins
Podcasts · May 9 · 16 mins
Mall-aysia: Why Are We Still Building Malls?